A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
Authors:
- Peter M. EllisPEPeter M. Ellis
- Quincy S. ChuQCQuincy S. Chu
- Natasha LeighlNLNatasha Leighl
- Scott A. LaurieSLScott A. Laurie
- Holger FritschHFHolger Fritsch
- Birgit Gaschler-MarkefskiBGBirgit Gaschler-Markefski
- Steve GyorffySGSteve Gyorffy
- Gerd MunzertGMGerd Munzert
- 1 January 2013
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (1) , 19-27
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cellsNature Communications, 2011
- Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1Developmental Cell, 2008
- Targeting cell cycle kinases and kinesins in anticancer drug developmentExpert Opinion on Drug Discovery, 2007
- Targeted anti-mitotic therapies: can we improve on tubulin agents?Nature Reviews Cancer, 2007
- Targeting polo-like kinase 1 for cancer therapyNature Reviews Cancer, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Polo-like kinases and oncogenesisOncogene, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Induction and down-regulation of PLK, a humanserine/threonine kinase expressed in proliferating cells andtumors.Proceedings of the National Academy of Sciences, 1994